Table 2.
Current Zika vaccines in clinical trial.
| Vaccine platform | Name | Immunogen | Adjuvant | Dose* | Sponsor | Phase I | Phase II |
|---|---|---|---|---|---|---|---|
| DNA | VRC5283 | prM-E | None | 4 mg IM (Phase I) and 4 mg vs. 8 mg IM (Phase II) | NIAID/VRC | NCT02996461 | NTC03110770 |
| VRC5288 | prM-E | None | 4 mg IM | NIAID/VRC | NCT02840487 | – | |
| GLS5700 | prM-E | None | 1,2 mg ID | GeneOne Life Science Inovio Pharmaceuticals | NCT02809443 NCT02887482 | – | |
| mRNA | mRNA-1325 | prM-E | None | – | Moderna Therapeutics | NCT03010489 | – |
| Inactivated Virus | ZPIV | virion | Alum | 5 μg IM | NIAID/WRAIR/BIDMC | NCT02963909 NCT02952833 NCT02937233 | – |
| BBV121 | virion | Alum | 2.5 μg vs. 5 μg vs. 10 μg IM | Bharat Biotech | CTRI/2017/05/008539 | – | |
| PIZV | virion | Alum | 2 μg vs. 5 μg vs. 10 μg IM | Takeda | NCT03343626 | – | |
| VLA1601 | virion | Alum | 2.5 μg vs. 5 μg vs. 10 μg IM | Valneva Emergent Biosolutions | NCT03425149 | – | |
| Viral Vectored | MV-ZIKV | prM-E | None | Low dose vs. High dose IM | Themis Biosciences | NCT02996890 | – |
| Ad26.ZIKV.001 | M-E | None | – | Janssen Vaccines | NCT03356561 | – |
*
IM, intramuscular; ID, intradermal.